{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T10:47:24Z","timestamp":1789901244421,"version":"4.0.1"},"reference-count":138,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.jtho.2016.05.027","type":"journal-article","created":{"date-parts":[[2016,6,10]],"date-time":"2016-06-10T02:45:55Z","timestamp":1465526755000},"page":"1819-1836","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC"],"prefix":"10.1016","volume":"11","author":[{"given":"Francesco","family":"Facchinetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Marabelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Charles","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Tiseo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2016.05.027_bib1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","article-title":"The immunobiology of\u00a0cancer immunosurveillance and immunoediting","volume":"21","author":"Dunn","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.jtho.2016.05.027_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.jtho.2016.05.027_bib3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2016.05.027_bib4","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2016.05.027_bib5","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2007.15.0284","article-title":"Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures","volume":"26","author":"Dieu-Nosjean","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib6","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1164\/rccm.201309-1611OC","article-title":"Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer","volume":"189","author":"Germain","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jtho.2016.05.027_bib7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrc2051","article-title":"Immunostimulatory monoclonal antibodies for cancer therapy","volume":"7","author":"Melero","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2016.05.027_bib8","first-page":"12","article-title":"CD28 and CTLA-4 coreceptor\u00a0expression and signal transduction","volume":"229","author":"Rudd","year":"2009","journal-title":"Immunol\u00a0Rev"},{"key":"10.1016\/j.jtho.2016.05.027_bib9","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1146\/annurev.immunol.21.120601.141135","article-title":"Does the immune system see tumors as foreign or self?","volume":"21","author":"Pardoll","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jtho.2016.05.027_bib10","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","article-title":"Immune escape mechanisms as a guide for cancer immunotherapy","volume":"21","author":"Beatty","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2016.05.027_bib11","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1158\/0008-5472.CAN-11-4094","article-title":"Cellular constituents of immune escape within the tumor microenvironment","volume":"72","author":"Kerkar","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2016.05.027_bib12","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2016.05.027_bib13","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2016.05.027_bib14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/annonc\/mdv489","article-title":"Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies","volume":"27","author":"Ilie","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","article-title":"Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer","volume":"2","author":"McLaughlin","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/pcmr.12340","article-title":"PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1\/PD-L1 clinical trials","volume":"28","author":"Madore","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jtho.2016.05.027_bib17","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1158\/1078-0432.CCR-14-2023","article-title":"PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor-treated melanoma patients","volume":"21","author":"Kakavand","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2016.05.027_bib18","doi-asserted-by":"crossref","first-page":"20090","DOI":"10.1038\/srep20090","article-title":"Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer","volume":"6","author":"Sheng","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2016.05.027_bib19","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jtho.2016.05.027_bib20","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib21","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2016.05.027_bib22","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2016.05.027_bib23","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2016.05.027_bib24","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2016.05.027_bib25","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1158\/2326-6066.CIR-15-0059","article-title":"Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells","volume":"3","author":"Boyerinas","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtho.2016.05.027_bib26","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2016.05.027_bib27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrclinonc.2015.209","article-title":"Combination cancer immunotherapies tailored to the tumour microenvironment","volume":"13","author":"Smyth","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib28","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib29","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2016.05.027_bib30","series-title":"Cancer Facts & Figures\u00a02014","year":"2014"},{"key":"10.1016\/j.jtho.2016.05.027_bib31","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/cncr.29098","article-title":"Small cell lung cancer: where do we go from here?","volume":"121","author":"Byers","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2016.05.027_bib32","doi-asserted-by":"crossref","first-page":"e7835","DOI":"10.1371\/journal.pone.0007835","article-title":"Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results","volume":"4","author":"Oze","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2016.05.027_bib33","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1158\/1078-0432.CCR-14-2958","article-title":"Small cell lung cancer: will recent progress lead to improved outcomes?","volume":"21","author":"Pietanza","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"suppl 2","key":"10.1016\/j.jtho.2016.05.027_bib34","first-page":"S192","article-title":"A\u00a0DLL3-targeted adc, rovalpituzumab tesirine, demonstrates substantial activity in a phase I study in relapsed and refractory SCLC","volume":"10","author":"Rudin","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib35","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/JTO.0b013e318286cf88","article-title":"Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches","volume":"8","author":"Spigel","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib36","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1158\/0008-5472.CAN-15-1502","article-title":"Plasticity beyond cancer cells and the \u201cimmunosuppressive switch\u201d","volume":"75","author":"Granot","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2016.05.027_bib37","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.imbio.2013.06.003","article-title":"Tumor associated\u00a0macrophages and neutrophils in cancer","volume":"218","author":"Galdiero","year":"2013","journal-title":"Immunobiology"},{"key":"10.1016\/j.jtho.2016.05.027_bib38","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.4049\/jimmunol.1403134","article-title":"Tumor-infiltrating dendritic cells in cancer pathogenesis","volume":"194","author":"Tran Janco","year":"2015","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jtho.2016.05.027_bib39","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3389\/fimmu.2015.00523","article-title":"Paving the road to tumor development and spreading: myeloid-derived suppressor cells are ruling the fate","volume":"6","author":"Meirow","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtho.2016.05.027_bib40","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.humimm.2015.09.006","article-title":"Regulatory B cell: new member of immunosuppressive cell club","volume":"76","author":"Ding","year":"2015","journal-title":"Hum Immunol"},{"key":"10.1016\/j.jtho.2016.05.027_bib41","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.coi.2015.02.003","article-title":"The interplay of effector and regulatory T cells in cancer","volume":"33","author":"Roychoudhuri","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jtho.2016.05.027_bib42","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/icb.2013.38","article-title":"Inactivation of tumor-specific CD8\u207a CTLs by tumor-infiltrating tolerogenic\u00a0dendritic cells","volume":"91","author":"Harimoto","year":"2013","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.jtho.2016.05.027_bib43","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3389\/fimmu.2015.00482","article-title":"Critical role of tumor microenvironment in shaping NK cell functions: implication of hypoxic stress","volume":"6","author":"Hasmim","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtho.2016.05.027_bib44","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fonc.2014.00070","article-title":"Control of the immune response by pro-angiogenic factors","volume":"4","author":"Voron","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib45","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2016.05.027_bib46","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1158\/0008-5472.CAN-12-4354","article-title":"Vascular normalization as an emerging strategy to enhance cancer immunotherapy","volume":"73","author":"Huang","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2016.05.027_bib47","first-page":"1875","article-title":"A\u00a0high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma","volume":"6","author":"Eerola","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2016.05.027_bib48","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1378\/chest.12-0681","article-title":"Histologic assessment of tumor-associated CD45(+) cell numbers is an independent predictor of prognosis in small cell lung cancer","volume":"143","author":"Wang","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.jtho.2016.05.027_bib49","doi-asserted-by":"crossref","first-page":"E928","DOI":"10.1002\/ijc.27613","article-title":"Small cell lung cancer tumour cells induce regulatory T lymphocytes, and patient survival correlates negatively with FOXP3+ cells in tumour infiltrate","volume":"131","author":"Wang","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2016.05.027_bib50","doi-asserted-by":"crossref","first-page":"6770","DOI":"10.1158\/1078-0432.CCR-08-1156","article-title":"Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage","volume":"14","author":"Koyama","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2016.05.027_bib51","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1378\/chest.105.6.1673","article-title":"Peripheral\u00a0blood lymphocyte subsets and survival in small-cell lung cancer","volume":"105","author":"Studnicka","year":"1994","journal-title":"Chest"},{"key":"10.1016\/j.jtho.2016.05.027_bib52","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/intimm\/dxr122","article-title":"Increased numbers but functional defects of CD56+CD3+ cells in lung cancer","volume":"24","author":"Al Omar","year":"2012","journal-title":"Int Immunol"},{"key":"10.1016\/j.jtho.2016.05.027_bib53","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s12032-008-9165-9","article-title":"CD8+CD28- cells and CD4+CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients","volume":"27","author":"Karag\u00f6z","year":"2010","journal-title":"Med Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib54","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2016.05.027_bib55","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jtho.2016.05.027_bib56","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2016.05.027_bib57","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jtho.2016.05.027_bib58","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jtho.2016.05.027_bib59","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2016.05.027_bib60","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.jtho.2016.05.027_bib61","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1474-4422(08)70060-7","article-title":"Paraneoplastic syndromes of the CNS","volume":"7","author":"Dalmau","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jtho.2016.05.027_bib62","doi-asserted-by":"crossref","first-page":"838","DOI":"10.4065\/mcp.2010.0099","article-title":"Paraneoplastic syndromes: an approach to diagnosis and treatment","volume":"85","author":"Pelosof","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jtho.2016.05.027_bib63","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1200\/JCO.1997.15.8.2866","article-title":"Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival","volume":"15","author":"Graus","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib64","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jns.2007.07.007","article-title":"Neurological course of long-term surviving patients with SCLC and anti-Hu syndrome","volume":"263","author":"Poepel","year":"2007","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.jtho.2016.05.027_bib65","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2016.05.027_bib66","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/JTO.0000000000000526","article-title":"Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art?","volume":"10","author":"Kerr","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib67","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/JTO.0000000000000414","article-title":"Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer","volume":"10","author":"Ishii","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib68","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/j.ejca.2015.06.003","article-title":"PD-L1 expression in small cell lung cancer","volume":"51","author":"Komiya","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2016.05.027_bib69","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ejca.2014.12.006","article-title":"PD-L1 expression in small cell neuroendocrine carcinomas","volume":"51","author":"Schultheis","year":"2015","journal-title":"Eur J Cancer"},{"issue":"suppl\u00a02","key":"10.1016\/j.jtho.2016.05.027_bib70","first-page":"S222","article-title":"Association of expression of PD-L1 with the tumor immune microenvironment in small cell lung cancer","volume":"10","author":"Yu","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib71","first-page":"1553","article-title":"Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung\u00a0cancer lines","volume":"5","author":"Yamane","year":"2015","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.jtho.2016.05.027_bib72","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/CCO.0000000000000263","article-title":"Predictive biomarkers for programmed death-1\/programmed death ligand immune checkpoint inhibitors in non small cell lung cancer","volume":"28","author":"Remon","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib73","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/annonc\/mds213","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial","volume":"24","author":"Reck","year":"2013","journal-title":"Ann Oncol"},{"issue":"suppl 4","key":"10.1016\/j.jtho.2016.05.027_bib74","first-page":"iv511","article-title":"A\u00a0novel phase II trial of ipilimumab, carboplatin and etoposide (ICE) for the first line treatment of extensive stage small cell\u00a0lung cancer (SCLC)","volume":"25","author":"Ottensmeier","year":"2014","journal-title":"Ann Oncol"},{"issue":"suppl 2","key":"10.1016\/j.jtho.2016.05.027_bib75","first-page":"S193","article-title":"Pembrolizumab for ED SCLC: efficacy and relationship with PD-L1 expression","volume":"10","author":"Ott","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl 3","key":"10.1016\/j.jtho.2016.05.027_bib76","doi-asserted-by":"crossref","first-page":"S633","DOI":"10.1016\/S0959-8049(16)31739-7","article-title":"Nivolumab monotherapy or in combination with ipilimumab for treatment of recurrent small cell lung cancer (SCLC)","volume":"5","author":"Calvo","year":"2015","journal-title":"Eur J Cancer"},{"issue":"suppl","key":"10.1016\/j.jtho.2016.05.027_bib77","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1200\/jco.2015.33.15_suppl.7503","article-title":"Phase I\/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032","volume":"33","author":"Antonia","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib78","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2016.05.027_bib79","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2011.38.4032","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB\/IV non-small-celllung cancer: results from a randomized, double-blind, multicenter phase II study","volume":"30","author":"Lynch","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib80","unstructured":"U.S. National Institutes of Health. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/home. Accessed March 31, 2016."},{"key":"10.1016\/j.jtho.2016.05.027_bib81","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/JTO.0000000000000074","article-title":"Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC","volume":"9","author":"Champiat","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib82","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.2174\/092986712800099866","article-title":"Modulation of inflammatory immune reactions by low-dose ionizing radiation: molecular mechanisms and clinical application","volume":"19","author":"R\u00f6del","year":"2012","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jtho.2016.05.027_bib83","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.4049\/jimmunol.1402711","article-title":"CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident\u00a0memory T cells and a prognostic factor for survival in lung cancer patients","volume":"194","author":"Djenidi","year":"2015","journal-title":"J\u00a0Immunol"},{"issue":"suppl 1","key":"10.1016\/j.jtho.2016.05.027_bib84","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/modpathol.2011.150","article-title":"Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas","volume":"25","author":"Travis","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2016.05.027_bib85","first-page":"718","article-title":"Latent period for malignant mesothelioma of occupational origin","volume":"34","author":"Lanphear","year":"1992","journal-title":"J\u00a0Occup Med"},{"key":"10.1016\/j.jtho.2016.05.027_bib86","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma","volume":"353","author":"Robinson","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2016.05.027_bib87","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/sj.bjc.6690105","article-title":"The European mesothelioma epidemic","volume":"79","author":"Peto","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2016.05.027_bib88","doi-asserted-by":"crossref","unstructured":"Francisci S, Minicozzi P, Pierannunzio D, et al. Survival patterns in lung and pleural cancer in Europe 1999-2007: results from the EUROCARE-5 study [E-pub ahead of print]. Eur J Cancer. http:\/\/dx.doi.org\/10.1016\/j.ejca.2015.07.033, accessed July 12, 2016.","DOI":"10.1016\/j.ejca.2015.07.033"},{"key":"10.1016\/j.jtho.2016.05.027_bib89","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2016.05.027_bib90","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1172\/JCI80007","article-title":"Immunity, inflammation, and cancer: an eternal fight between good and evil","volume":"125","author":"Shalapour","year":"2015","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtho.2016.05.027_bib91","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.ajpath.2012.12.028","article-title":"New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas","volume":"182","author":"Mossman","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jtho.2016.05.027_bib92","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.semcancer.2015.08.008","article-title":"Complexity in the tumour microenvironment: Cancer associated fibroblast gene expression patterns identify both common and unique features of tumour-stroma crosstalk across cancer types","volume":"35","author":"Gandellini","year":"2015","journal-title":"Semin Cancer Biol"},{"issue":"suppl","key":"10.1016\/j.jtho.2016.05.027_bib93","doi-asserted-by":"crossref","first-page":"7589","DOI":"10.1200\/jco.2014.32.15_suppl.7589","article-title":"T-cell inflamed phenotype and PDL1 expression in malignant mesothelioma","volume":"32:5s","author":"Kindler","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2016.05.027_bib94","doi-asserted-by":"crossref","first-page":"7566","DOI":"10.1200\/jco.2015.33.15_suppl.7566","article-title":"Immune escape correlates with an inflamed phenotype in malignant mesothelioma","volume":"33","author":"Khattri","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib95","doi-asserted-by":"crossref","first-page":"e1009285","DOI":"10.1080\/2162402X.2015.1009285","article-title":"The tumoral and stromal immune microenvironment in malignant pleural\u00a0mesothelioma: A comprehensive analysis reveals prognostic immune markers","volume":"4","author":"Ujiie","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtho.2016.05.027_bib96","doi-asserted-by":"crossref","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedr\u00e9s","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2016.05.027_bib97","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib98","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2016.01.010","article-title":"Immune biomarkers PD-1\/PD-L1 and TLR3 in malignant pleural mesotheliomas","volume":"52","author":"Combaz-Lair","year":"2016","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jtho.2016.05.027_bib99","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabr\u00f2","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib100","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study","volume":"3","author":"Calabr\u00f2","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2016.05.027_bib101","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib102","unstructured":"AstraZeneca. AstraZeneca reports top-line result of tremelimumab monotherapy trial in mesothelioma. https:\/\/www.astrazeneca.com\/our-company\/media-centre\/press-releases\/2016\/astrazeneca-reports-top-line-result-of-tremelimumab-monotherapy-trial-in-mesothelioma-29022016.html. Accessed July 12, 2016."},{"key":"10.1016\/j.jtho.2016.05.027_bib103","doi-asserted-by":"crossref","first-page":"CT103","DOI":"10.1158\/1538-7445.AM2015-CT103","article-title":"Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: Preliminary results from KEYNOTE-028","volume":"75","author":"Alley","year":"2015","journal-title":"Cancer Res"},{"issue":"suppl 2","key":"10.1016\/j.jtho.2016.05.027_bib104","first-page":"S195","article-title":"Single-agent pembrolizumab for patients with malignant pleural mesothelioma (MPM)","volume":"10","author":"Alley","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl 3","key":"10.1016\/j.jtho.2016.05.027_bib105","doi-asserted-by":"crossref","first-page":"S639","DOI":"10.1016\/S0959-8049(16)31751-8","article-title":"Safety and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced, unresectable mesothelioma:\u00a0a phase Ib trial","volume":"51","author":"Hassan","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2016.05.027_bib106","unstructured":"Kindler HL. Immunotherapy for mesothelioma. CTLA4 and PD-1. Minisymposium S17.04 presented at the 16th World Congress on Lung Cancer. September 8, 2015; Denver, CO."},{"key":"10.1016\/j.jtho.2016.05.027_bib107","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and\u00a0checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib108","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/j.seminoncol.2015.02.010","article-title":"Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies","volume":"42","author":"Eggermont","year":"2015","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib109","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.cell.2015.09.001","article-title":"Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity","volume":"163","author":"Serrels","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2016.05.027_bib110","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2016.05.027_bib111","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1158\/1078-0432.CCR-06-1893","article-title":"Prospect of targeting the CD40 pathway for cancer therapy","volume":"13","author":"Vonderheide","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2016.05.027_bib112","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1186\/1471-2407-14-969","article-title":"The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40","volume":"14","author":"Khong","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2016.05.027_bib113","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1093\/annonc\/mdv387","article-title":"A\u00a0phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in\u00a0malignant pleural mesothelioma","volume":"26","author":"Nowak","year":"2015","journal-title":"Ann Oncol"},{"issue":"suppl 2","key":"10.1016\/j.jtho.2016.05.027_bib114","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1097\/JTO.0000000000000299","article-title":"Alterations of the immune system in thymic malignancies","volume":"9","author":"Weksler","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib115","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jtho.2015.11.012","article-title":"Thymic epithelial tumor-associated cytopenia: a 10-year observational study in france","volume":"11","author":"Rivoisy","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib116","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/JTO.0000000000000393","article-title":"The impact of thymoma histotype on prognosis in a worldwide database","volume":"10","author":"Weis","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib117","first-page":"756","article-title":"Paraneoplastic diseases associated with thymoma","volume":"254","author":"Evoli","year":"2007","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.jtho.2016.05.027_bib118","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1093\/ejcts\/ezv380","article-title":"Myasthenia gravis with thymic epithelial tumour: a retrospective analysis of a Japanese database","volume":"49","author":"Nakajima","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.jtho.2016.05.027_bib119","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/35095500","article-title":"Lymphostromal interactions in thymic development and function","volume":"1","author":"Anderson","year":"2001","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jtho.2016.05.027_bib120","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev.immunol.21.120601.141107","article-title":"Positive and negative selection of T cells","volume":"21","author":"Starr","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jtho.2016.05.027_bib121","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1196\/annals.1405.018","article-title":"Common cellular and diverse genetic basis of thymoma-associated myasthenia gravis: role of MHC class II and AIRE genes and genetic polymorphisms","volume":"1132","author":"Str\u00f6bel","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jtho.2016.05.027_bib122","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/path.2141","article-title":"Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1)","volume":"211","author":"Str\u00f6bel","year":"2007","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.jtho.2016.05.027_bib123","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1365-2249.2007.03442.x","article-title":"Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas","volume":"149","author":"Scarpino","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jtho.2016.05.027_bib124","first-page":"743","article-title":"Abnormal thymocyte development and generation of autoreactive T cells in mixed and cortical thymomas","volume":"78","author":"Nenninger","year":"1998","journal-title":"Lab Invest"},{"issue":"suppl 4","key":"10.1016\/j.jtho.2016.05.027_bib125","doi-asserted-by":"crossref","first-page":"S286","DOI":"10.1097\/JTO.0b013e3181f209a8","article-title":"Thymoma and thymic carcinoma: molecular pathology and targeted therapy","volume":"5","author":"Str\u00f6bel","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib126","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.athoracsur.2003.07.042","article-title":"WHO histologic classification is a prognostic indicator in thymoma","volume":"77","author":"Kondo","year":"2004","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2016.05.027_bib127","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/JTO.0000000000000654","article-title":"The 2015 World Health Organization classification of tumors of the thymus: continuity and changes","volume":"10","author":"Marx","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib128","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.lungcan.2011.03.008","article-title":"Prognostic effect of stromal lymphocyte infiltration in thymic carcinoma","volume":"74","author":"Shim","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2016.05.027_bib129","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.4049\/jimmunol.170.3.1257","article-title":"Blockade of programmed\u00a0death-1 ligands on dendritic cells enhances T cell activation and cytokine production","volume":"170","author":"Brown","year":"2003","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jtho.2016.05.027_bib130","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","article-title":"Diffuse high intensity PD-L1 staining in thymic epithelial tumors","volume":"10","author":"Padda","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib131","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2015.03.003","article-title":"Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma","volume":"88","author":"Katsuya","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2016.05.027_bib132","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.athoracsur.2015.10.044","article-title":"Clinicopathologic and prognostic implications of Programmed Death Ligand 1 expression in thymoma","volume":"101","author":"Yokoyama","year":"2016","journal-title":"Ann Thorac Surg"},{"issue":"suppl 2","key":"10.1016\/j.jtho.2016.05.027_bib133","first-page":"S510","article-title":"The clinicopathological significance of PD-L1 expression in thymoma","volume":"10","author":"Takumi","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2016.05.027_bib134","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.1200\/jco.2015.33.15_suppl.7516","article-title":"Defining the immunologic phenotype of thymic epithelial tumors","volume":"33","author":"Naidoo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib135","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/annonc\/mdu527","article-title":"Available evidence\u00a0and new biological perspectives on medical treatment of advanced thymic epithelial tumors","volume":"26","author":"Serpico","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib136","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients\u00a0with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2016.05.027_bib137","unstructured":"Giaccone G, Thompson J, Crawford J, et\u00a0al. Phase II study of pembrolizumab in patients with recurrent thymic carcinoma. Presentation O5.5. at the 14th Target Anticancer Therapies Congress. March 21\u201321, 2016; Washington, DC."},{"key":"10.1016\/j.jtho.2016.05.027_bib138","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1556086416305020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1556086416305020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T00:52:18Z","timestamp":1600735938000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086416305020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":138,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S1556086416305020"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2016.05.027","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"http:\/\/dx.doi.org\/10.1016\/j.jtho.2016.05.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}